Biogen Inc. (BIIB)
Symbol Info
Listed Symbol BIIB
Name Biogen Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $12,867,000,000
Latest Fiscal EPS $21.62
Price Info
21 Day Moving Average $230.4086
21 Day EMA $227.430660
50 Day Moving Average $229.9642
50 Day EMA $229.886340
200 Day EMA $252.946600
200 Day Moving Average 258.078100
52 Week High $344.00
52 Week Low $215.78
52 Week Change $-31.796398
Alpha -0.008910
Beta 0.9907
Standard Deviation 0.089184
R2 0.145675
Periods 60
Share Information
10 Day Average Volume 1,775,686
20 Day Average Volume 1,726,601
30 Day Average Volume 1,661,352
50 Day Average Volume 1,464,156
Outstanding Shares 184,447,218
Float Shares 182,476,536
Percent Float 98.93%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 2,245
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 11,067,720
Institute Holdings Percent -
Institute Sold Previous 3 Months 34,619,126
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,970,682
Price Change
7 Day Price Change $-0.7899933
7 Day Percent Change -0.35%
21 Day Price Change $-15.579987
21 Day Percent Change -6.52%
30 Day Price Change $-12.75
30 Day Percent Change -5.40%
Month To Date Price Change $-9.61
Month To Date Percent -4.13%
90 Day Price Change $-8.389999
90 Day Percent Change -3.62%
Quarter To Date $-9.610001
Quarter To Date Percent -4.13%
180 Day Price Change $-10.619995
180 Day Percent Change -4.54%
200 Day Price Change $2.950012
200 Day Percent Change 1.34%
Year To Date $-77.71001
Year To Date Percent -25.82%
Profile
Description Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.
Details
Issue Type CS
Market Cap $41,170,463,530
Sec Type EQS
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 184,447,218
CEO
Employees 7,800
Last Audit UE
Classification
CIK 0000875045
Industry Drug Manufacturers
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 225 Binney Street
Cambridge, MA 2142
Website http://www.biogen.com
Facisimile +1 302 636-5454
Telephone +1 617 679-2000
Email IR@biogen.com
Key Ratios
Profitability
EBIT Margin 50.00
EBITDA Margin 56.5
Pre-Tax Profit Margin 42.7
Profit Margin Cont 38.44
Gross Margin 85.60
Profit Margin TOT 38.44
Income Statements
Revenue $10,014,700,000
Revenue Per Share $54.2958
Revenue 3 Years $0.62
Revenue 5 Years $5.03
Valuation Measures
PE Ratio 8.20
Enterprise Value $46,362,301,294
Price To Sales 4.111003
Price To Free Cash 11.900000
PE High Last 5 Years 42.6
Price To Book 3.2
Price To Cash Flow 6.2
PE Low Last 5 Years 13.4
Price To Tangible Book 11.6
Financial Strength
Total Debt To Equity 0.5
Int Coverage 36.1
Current Ratio 2.5
Leverage Ratio 2.0
Quick Ratio 1.7
Long Term Debt To Capital 0.33
Assets
Receivables Turnover 4.3
Invoice Turnover 2.10
Assets Turnover 0.40
Management Effectiveness
Return Assets 21.33
Return On Equity 42.51
Return On Capital 28.54
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
BIIB
Biogen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.